High treatment efficacy by dual targeting of Burkitt’s lymphoma xenografted mice with a 177Lu-based CD22-specific radioimmunoconjugate and rituximab
Dual-targeted therapy has been shown to be a promising treatment option in recurrent and/or refractory B-cell non-Hodgkin’s lymphoma (B-NHL). We generated radioimmunoconjugates (RICs) comprising either a novel humanized anti-CD22 monoclonal antibody, huRFB4, or rituximab, and the low-energy β-emitte...
Gespeichert in:
| Hauptverfasser: | , , , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
2016
|
| In: |
European journal of nuclear medicine and molecular imaging
Year: 2015, Jahrgang: 43, Heft: 3, Pages: 489-498 |
| ISSN: | 1619-7089 |
| DOI: | 10.1007/s00259-015-3175-6 |
| Online-Zugang: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1007/s00259-015-3175-6
|
| Verfasserangaben: | Tobias Weber, Benedikt Bötticher, Walter Mier, Max Sauter, Susanne Krämer, Karin Leotta, Armin Keller, Anne Schlegelmilch, Ludger Grosse-Hovest, Dirk Jäger, Uwe Haberkorn, Michaela A.E. Arndt, Jürgen Krauss |
| Zusammenfassung: | Dual-targeted therapy has been shown to be a promising treatment option in recurrent and/or refractory B-cell non-Hodgkin’s lymphoma (B-NHL). We generated radioimmunoconjugates (RICs) comprising either a novel humanized anti-CD22 monoclonal antibody, huRFB4, or rituximab, and the low-energy β-emitter 177Lu. Both RICs were evaluated as single agents in a human Burkitt’s lymphoma xenograft mouse model. To increase the therapeutic efficacy of the anti-CD22 RIC, combination therapy with unlabelled anti-CD20 rituximab was explored. |
|---|---|
| Beschreibung: | Published online: 04 September 2015 Im Titel ist die Zahl "177" hochgestellt Gesehen am 18.05.2020 |
| Beschreibung: | Online Resource |
| ISSN: | 1619-7089 |
| DOI: | 10.1007/s00259-015-3175-6 |